Literature DB >> 26223961

Surveillance of waiting times for access to treatment: a registry-based computed approach in breast cancer care.

A Quillet1, G Defossez1, P Ingrand1,2.   

Abstract

The current study set out to automatically generate waiting times for access to surgery, chemotherapy and radiotherapy, and to analyse their determinants for non-metastatic breast cancer patients. We used data from the Poitou-Charentes regional cancer registry of women diagnosed with stages I-III breast carcinoma between 2008 and 2010. Waiting times were automatically computed from a previously validated algorithm modelling the care trajectory and then compared with national guidelines. The population of this study included 1082 patients. The compliance with guidelines ranged from 52.4% (access to adjuvant chemotherapy) to 89.2% (access to adjuvant radiotherapy). Younger age, a higher TNM stage, a lower grade, having a triple negative tumour, being the subject of multidisciplinary meetings and being a patient at a public hospital were associated with longer waiting times. The main result was the significant heterogeneity between geographical areas of treatment for all waiting times studied. The original, reproducible use of a registry-based automated algorithm to generate waiting times will help to follow these indicators routinely and efficiently.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  automatic data processing; breast cancer; cancer registry; waiting times

Mesh:

Year:  2015        PMID: 26223961     DOI: 10.1111/ecc.12362

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  2 in total

Review 1.  Multidisciplinary care of breast cancer patients: a scoping review of multidisciplinary styles, processes, and outcomes.

Authors:  J Shao; M Rodrigues; A L Corter; N N Baxter
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

2.  Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.

Authors:  Gautier Defossez; Alexandre Quillet; Pierre Ingrand
Journal:  BMC Cancer       Date:  2018-04-06       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.